Market Perform - Price 269.69 on Nov. 17
by Morgan Keegan

We derive a fair-value range of $256 to $315, based on our 10-year discounted-cash-flow, price/earnings, and enterprise value/Ebitda [earnings before interest, taxes, depreciation and amortization] analyses. The da Vinci system is at the forefront of robotic surgery, driving the shift from conventional minimally invasive surgery. ISRG has 1,300-plus systems installed worldwide, [with] 7,000 sites targeted. For 2008-11, we forecast revenue and EPS growth of 19% and 16%, respectively, assuming a 35% rise in surgical procedures. We recognize that great growth stories do not come cheap, but our valuation methodologies guard us from being more aggressive now....The stock has rebounded 200%-plus from March lows... and now trades at 39 times our '10 EPS forecast. Capital spending and adoption of procedures appear to be the greatest variables to growth...Market cap: $10.7 billion.

originally bought this @ $40, it's been Very good to me!

explosive

heart surgery

Hitting a Grand Slam in earnings and the short squeeze is on.

Fantastic stk

Robotic surgery is the wave of future medicine...and it's happening now.

it keeps climbing

help to save people's life

Future of robotic surgery should be great.

I found the gyrations hit me big time because it is an expensive stock, U can be up or down hundreds or thousands in a short span.

poor valuations

Much loved, high P/E.

too expansive

short

costly mistake

i missed the buy in before it took off

Way overvalued

P/E too high and stock went up too fast

too expensive for now